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and bilateral renal artery stenosis, or unilateral renal 
artery stenosis of the only kidney. Clinical and laboratory 
symptoms of cardio-renal syndrome include progressive 
heart and kidney failure with refractory hypertension and 
vascular disease, difference in size of the kidneys by more 
than 1.5 cm, and reversible creatinine level increase caused 
by angiotensin convertase inhibitors.
CASE REPORT
A 58 year old male, a known case of ischaemic heart disease 
with Type 2 Diabetes mellitus and hypertension, who had 
been admitted for cerebellar stroke 2 months back, came 
with complaints of dry cough- (more at night), gradually 
increasing breathlessness (New York Heart Association, 
NYHA Grade-I to start with and displaying gradual 
progression to NYHA Grade IV in a period of 3 days), 
and swelling all over the body with minimal abdominal 
distension. Patient was admitted in Intensive Cardiac-Care 
Unit (ICCU). On admission, his blood pressure (BP) was 
170/100  mmHg; pallor and icterus were present, and 
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ABSTRACT
Cardiac and renal diseases are becoming increasingly common today, and are seen to frequently coexist, 
thus causing a significant increase in the mortality rate, morbidity, complexity of treatment and cost of care. 
Syndromes describing the interaction between heart and kidney have been defined and classified; however, 
never as a result of a consensus process. Though the incidence of cardiorenal syndrome is increasing, the 
associated pathophysiology and effective management are still not well understood. For many years, diuretics 
and ultrafiltration, have been the mainstay of treatment for cardiorenal syndrome, although a significant 
proportion of patients develop resistance to diuretics, and even deteriorate while on diuretics. Here, we will 
discuss one such patient who failed to respond to the optimum doses of diuretics; however, his blood urea and 
serum creatinine touched the baseline levels post-ultrafiltration.
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INTRODUCTION
Cardiorenal syndrome is a term connoting the intersection 
between cardiac and renal dysfunctions, most frequently 
in patients with heart failure. Although the underlying 
mechanisms have not been fully characterized, this 
presentation in the setting of acute decompensated heart 
failure and in chronic heart failure is associated with poor 
short- and long-term outcomes. Cardio-renal syndrome can 
be diagnosed in the following conditions: Hypervolaemia 
in advanced renal failure, co-occurrence of heart and 
kidney failure (eg, ischemic heart disease and obstructive 
arterial disease), malignant hypertension leading to the 
development of simultaneous heart and kidney failure, 
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jugular veins showed distension. Also, facial puffiness was 
present along with bipedal pitting oedema. Per abdominal 
examination was suggestive of moderate ascites with no 
organomegaly. Respiratory system examination revealed 
bilaterally reduced breath sounds at lung bases, with a 
stony dull note and extensive scattered coarse crepitations.
On investigation, his total leukocyte count was 18900/ cmm, 
and blood sugar levels were constantly on higher side. His 
liver function test report was as follows: Total bilirubin-2.8 
mg/dl; direct bilirubin-1.2 mg/dl; indirect bilirubin-1.6 mg/
dl; serum glutamic pyruvic transaminase (SGPT)-23 IU; 
serum glutamic oxaloacetic transaminase (SGOT) -61 IU; 
alkaline phosphatise-175; blood urea-90 mg/dl and serum 
creatinine-3 mg/dl. Electrocardiography (ECG) was showing 
sinus bradycardia with ST segment depression in inferior, 
anterior, lateral leads with left ventricular hypertrophy 
(LVH) and multiform ventricular premature beats. 2-D 
Echocardiography revealed all four heart chambers to be 
dilated with concentric left ventricular (LV) hypertrophy, 
global hypokinesia, LV ejection fraction of 37%, moderate 
LV systolic dysfunction, grade III diastolic dysfunction, 
mild mitral regurgitation, moderate tricuspid regurgitation 
and moderate pulmonary artery hypertension. Urine output 
was less than 30ml/hr. Chest radiograph was suggestive of 
bilateral hydrothorax. Ultrasonography of the abdomen and 
pelvis showed bilateral pleural effusion with moderate ascites 
with dilated inferior vena cava (IVC) and portal vein while the 
kidneys appeared smaller in size. The provisional diagnosis 
turned out to be Cardiorenal Syndrome (CRS) Type II which 
was finally confirmed by a cardiologist’s expert opinion.
During his stay in ICCU, he was treated with immediate 
haemodialysis (mainly ultrafiltration), medical intervention 
with nitrates, antiplatelets and furosemide, along with other 
supportive care. After one session of haemodialysis, his 
general condition improved and his serum creatinine level 
came down to 1.8 mg/dl [normal range → 0.8-1.6 mg/dl]. 
After being stable for one day, his urine output reduced, 
for which he was started on intravenous furosemide (60-
mg bolus followed by continuous infusion of 5 mg/hour), 
which showed only a moderate diuretic response (1800 to 
2000 mL/day). This was continued for 2 days. However, 
he continued to be oliguric and gained 2 kg of body weight 
on the third day of intravenous (IV) furosemide, and 
serum creatinine and blood urea nitrogen concentrations 
rose from 1.8 to 2.7 mg/dL and from 53 to 125 mg/dL, 
respectively. Thus, suspecting the diuretic resistance in 
CRS, he was dialysed immediately on the 4th day which 
led to dramatic improvement and drop in blood urea level 
to- 33 mg/dl and serum creatinine level to 1.4 mg/dl. 
Antibiotic cover was given with Moxifloxacin 400 mg IV 
per day. He was also put on low salt and a strict diabetic 
diet along with subcutaneous regular human insulin daily 
as per his body-requirement. He was monitored for cardio-
pulmonary status and input-output records round the clock. 
Further management with oral furosemide showed gradual 
improvement in his cardiorenal status by lowering renal 
markers and improved urine output to around 2000 ml 
per day, thus making him totally symptom-free. Patient was 
later on discharged in a haemodynamically stable condition, 
and was advised regular once a week haemodialysis 
(ultrafiltration) along with other supportive care.
DISCUSSION
The term “Cardiorenal Syndrome” is generally used to 
describe the presence or development of renal dysfunction 
in patients with cardiac dysfunction. Although most patients 
with this presentation are volume overloaded, some patients 
may not be in congestive cardiac failure (CCF) and may suffer 
from low cardiac output. Renal dysfunction is one of the most 
powerful independent adverse prognostic predictors in heart 
failure patients. Cardiac dysfunction and renal dysfunction 
often occur concomitantly as they share common causes 
and pathogenic mechanisms. Diabetes and hypertension are 
among the most important causes of both heart failure and 
chronic kidney disease, and thus they are frequently associated 
with the cardiorenal syndrome and worsening renal function 
in patients hospitalized for heart failure,[1,2] just as in our case. 
Renovascular disease has also been implicated, especially in 
some case series, but there is inadequate data to determine 
its prevalence or mechanistic role in cardiorenal syndrome.[3]
Cardiorenal syndrome is common, with an estimated 
glomerular filtration rate (GFR) of less than 60 mL/
min/1.73 m2, is present in 33% of the patients with a recent 
myocardial infarction and left ventricular dysfunction or 
heart failure, and in up to 64% of the patients admitted 
for acute decompensated heart failure.[4]
Five subtypes of the syndromes have been identified and 
defined, as follows:
•  Acute Cardio-Renal Syndrome (Type 1): An acute 
worsening of cardiac function leading to renal 
dysfunction;
•  Chronic Cardio-Renal Syndrome (Type 2): Chronic 
abnormalities in cardiac function leading to renal 
dysfunction;
•  Acute Reno-Cardiac Syndrome (Type 3): An 
acute worsening of renal function causing cardiac 
dysfunction;
•  Chronic Reno-Cardiac Syndrome (Type 4): Chronic 
abnormalities in renal function leading to cardiac 
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•  Secondary Cardio-Renal Syndromes (Type 5): Systemic 
conditions causing simultaneous dysfunction of the 
heart and kidney.
In CRS Type II, the background pathophysiology is 
thought to be poor cardiac output that leads to activa  tion 
of renin-angiotensin-aldosterone system (RAAS) and 
negative myocardial remodelling. Although this concept is 
the prevailing one, it may not be the only pathophysiologic 
mechanism lead  ing to worsening renal function. The 
feed-forward mechanisms of Ang II and increased 
inflammatory markers and reactive oxygen species further 
exacerbate these abnormalities.[5] At present, there is no 
therapeutic intervention with proven benefit in outcomes 
in this setting, but reasonable treatment objectives include 
maintaining renal perfusion by maintaining arterial pressure, 
decongesting the patient to lessen central venous pressure, 
avoiding excessive diuresis, and maintaining as much as 
possible treatment with neurohormonal antagonists that 
are known to prolong survival and to prevent readmissions. 
Novel approaches in the form of the uses of nesiritide and 
adenosine antagonist (BG9719), vasopressin V2 receptor 
antagonist (tolyaptyan) are undergoing investigation. Role 
of diuretic agents are as follows:
Diuretics
Diuretics are a mainstay of treatment of patients with acute 
decompensated heart failure as they relieve fluid retention 
and congestion. However, high doses or excessive use of 
diuretics is associated with worsening renal function, at 
least in part by activating tubuloglomerular feedback and 
neurohormonal activation. Diuretic resistance is a hallmark 
of advanced heart failure and cardiorenal syndrome. It also 
increases renal dysfunction as measured by an increase in 
serum creatinine and declining GFR.[6,7]
Ultrafiltration
New devices using venovenous ultrafiltration provide a 
relatively simple approach to mechanical fluid removal, 
making this approach available in a variety of clinical 
settings. Compared with diuretic treatment, ultrafiltration 
is not associated with as much neurohormonal activation. It 
also facilitates greater and more rapid removal of fluid and, 
especially, of salt than does aggressive diuresis. One study 
suggested that although ultrafiltration was not associated 
with either greater symptom improvement or better renal 
function in a prospective randomized trial compared 
with furosemide, there was an apparent reduction in 
readmissions for heart failure between 30 and 90 days 
after discharge — a potentially important finding but one 
that requires replication.[8] Therefore, we want to conclude 
that most of the current therapies in use may not have the 
desired outcome on renal function; hence, good clinical 
judgement is essential for proper patient management. 
Diuretics act only as supportive care, and the mainstay of 
treatment is ultrafiltration. Patients diagnosed to be having 
CRS should be immediately treated with ultrafiltration 
along with diuretics as an add-on therapy, as, if not treated 
with ultrafiltration, these patients may require re-admission 
to the hospital in their near future, with the only treatment 
option as ultrafiltration. Further, —in depth studies are 
still necessary to understand the exact pathophysiology of 
cardiorenal syndrome and to determine an effective means 
of therapy in order to improve the patient outcome.
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